Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Brian S. Posner

At a glance: Brian S. Posner is Director at Dyne Therapeutics (DYN). Their latest SEC Form 4, filed Oct 6, 2026, reported a purchase of $40K. On file: 8 purchase lines ($315K) and 3 sale lines ($145K).

Disclosed holdings: about $435K of DYN stock: 27,000 shares reported on their latest Form 4 (filed Oct 6, 2026), valued at the Nov 19, 2026 close of $16.12. This counts only DYN shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

Director at Arch Capital Group Ltd. (ACGL); Director at Dyne Therapeutics, Inc. (DYN)

Purchase track record

Strong record. Based on 7 purchases with a full 90 days of price history.

86
Avg. 90-day return+22.7%
vs. S&P 500+15.7%
Beat the market71%
Paper profit on buys−$17K
Total bought / sold$315K / $145K

Brian S. Posner's InsiderPrint

16 trades from SEC Form 4 filings, 2020 to 2026, drawn as one fingerprint.

InsiderPrint of Brian S. Posner: 16 trades, 2020 to 20262020: 2 buys, 0 sales2021: 0 buys, 0 sales2022: 2 buys, 0 sales2023: 0 buys, 0 sales2024: 0 buys, 0 sales2025: 1 buy, 0 sales2026: 8 buys, 3 sales

Reading this print: Mostly buys, trading about 2 times a year, typically $38K a trade.

  • Bump outward: a purchase (13)
  • Dent inward: a sale (3)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Insiders with a similar print

  1. Eric R. NewellCFO · EGBN · 98% match
  2. Adam H. StedhamPresident · OPNW · 98% match
  3. Avrohom J. KessGeneral Counsel · TRV · 98% match
  4. Lori A. WoodsDirector · CATX · 98% matchTheir buys since 2023: 3 of 3 beat the S&P 500
  5. David A. PeacockCEO · ADV · 98% matchTheir buys since 2023: 6 of 12 beat the S&P 500

Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.

Every purchase since 2020

From the SEC's insider data sets: each open-market buy by Brian S. Posner, matched to how the stock did over the next 90 days against the S&P 500.

2 of 4 buys beat the S&P 500 (50%), median +0.7% vs. the index. Small sample: treat with care. All insider buys: 46%.

StockFiled90 days vs. S&P 500
ACGLAug 4, 2025-10.8%
ACGLNov 1, 2022+10.8%
ACGLMay 2, 2022-3.1%
ACGLMay 20, 2020+4.4%

Buys made close together in one stock count once. Price-only returns; history, not a prediction.

Reported trades

Filed Stock Type Shares Price Value Since
Oct 6SEC DYNDyne Therapeutics, Inc.Before earningsPast buys 2/4 beat S&P Buy 2,50027,000 held (+10%) $16.00 $40K +0.8%
Jun 9SEC DYNDyne Therapeutics, Inc.Buy #4 in 60 daysPast buys 2/4 beat S&P Buy 2,00024,500 held (+9%) $16.94 $34K -4.8%
Jun 5SEC DYNDyne Therapeutics, Inc.Buy #3 in 60 daysPast buys 2/4 beat S&P Buy 2,50022,500 held (+12%) $17.48 $44K -7.8%
Jun 4SEC ACGLArch Capital Group Ltd. Sell 3,000 $19.66 $59K —
May 28SEC DYNDyne Therapeutics, Inc.Buy #3 in 60 daysPast buys 2/4 beat S&P Buy 2,00020,000 held (+11%) $18.21 $36K -11.5%
May 22SEC DYNDyne Therapeutics, Inc.Past buys 2/4 beat S&P Buy 2,50018,000 held (+16%) $17.12 $43K -5.8%
May 12SEC ACGLArch Capital Group Ltd. Sell 2,000 $17.14 $34K —
Apr 1SEC DYNDyne Therapeutics, Inc.First buyBuy #3 in 60 daysPast buys 2/4 beat S&P Buy 2,00015,500 held (+15%) $17.08 $34K -5.6%
Mar 13SEC DYNDyne Therapeutics, Inc.First buyPast buys 2/4 beat S&P Buy 2,00013,500 held (+17%) $19.35 $39K -16.7%
Mar 12SEC ACGLArch Capital Group Ltd. Sell 3,0002,000 held (−60%) $17.11 $51K —
Mar 10SEC DYNDyne Therapeutics, Inc.First buyPast buys 2/4 beat S&P Buy 3,00011,500 held (+35%) $15.06 $45K +7.0%
  • Sell

    Director Brian S Posner sold $51K of ACGL at $17.11 — cuts the stake by 60%.

  • Buy

    Director Brian S Posner bought $45K of DYN at $15.06 — first open-market purchase in our records; raises the stake by 35%.

Follow Brian S. Posner

Get one email when Brian S. Posner files a new purchase or sale. Free.

At most one email a day about Brian S. Posner, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.